You are here

Bristol-Myers Squibb

5 Best-Selling Orphan Drugs in the U.S.

5 Best-Selling Orphan Drugs in the U.S.

Motley Fool

Teva Pharmaceutical

Bristol-Myers Squibb

Flag link:

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Endpoints

non-squamous non-small cell lung cancer

Bristol-Myers Squibb

Flag link:

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Yahoo/Benzinga

European Society of Cardiology

Celldex Therapeutics

Jounce Therapeutics

Bristol-Myers Squibb

Flag link:

BMY Is Rapidly Advancing Its First-Line NSCLC Research Program

BMY Is Rapidly Advancing Its First-Line NSCLC Research Program

Market Realist

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

Cancer drug spending climbs, with top winners earning lion's share

Cancer drug spending climbs, with top winners earning lion's share

Biopharma Dive

Bristol-Myers Squibb

Flag link:

5 takeaways from the first look at cancer's biggest conference

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Bristol-Myers Squibb

Jounce Therapeutics

Flag link:

Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen

Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen

Fierce Pharma

digital marketing

Bristol-Myers Squibb

Flag link:

EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer

EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer

CP Wire

Bristol-Myers Squibb

metastatic non-small cell lung cancer

Flag link:

EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

Medical Marketing and Media

Bristol-Myers Squibb

Flag link:

Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers

Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers

Forbes

Flatiron Health

Bristol-Myers Squibb

real-world evidence

Flag link:

Bristol-Myers profit tops Street view, raises 2018 forecast

Bristol-Myers profit tops Street view, raises 2018 forecast

Reuters

Bristol-Myers Squibb

Flag link:

Immunotherapies, biosimilars to dominate next week of earnings

Immunotherapies, biosimilars to dominate next week of earnings

Biopharma Dive

Bristol-Myers Squibb

Vertex Pharmaceuticals

Flag link:

Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

CP Wire

Bristol-Myers Squibb

Flag link:

Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer

Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Bristol-Myers Squibb

Flag link:

Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more

Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more

CNBC

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated

We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated

San Francisco Gate, CA

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

Bristol Partners With Illumina On Diagnostic Test To Use With Opdivo

Bristol Partners With Illumina On Diagnostic Test To Use With Opdivo

Forbes

Bristol-Myers Squibb

Flag link:

With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge

With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Pages